Unlock instant, AI-driven research and patent intelligence for your innovation.

Ipragliflozin L-proline tablet composition

A ‐proline and composition technology, applied in the field of iglitazone composition, can solve the problems of high adverse reactions, affecting clinical application, etc., and achieve the effect of stable performance

Inactive Publication Date: 2018-01-09
WEIHAI GUANBIAO INFORMATION TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Although Ipagliflozin has a good hypoglycemic effect, its chance of causing urinary tract infection is as high as 20%
Such a high adverse reaction affects its clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ipragliflozin L-proline tablet composition
  • Ipragliflozin L-proline tablet composition
  • Ipragliflozin L-proline tablet composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1, Ipagliflozin L-proline 10g, glimepiride 2g, chitosan 8g, calcium hydrogen phosphate 16g, microcrystalline cellulose 28g, povidone K30 3g, micronized silica gel 8g, stearic acid Magnesium 1g. Prepare 1000 tablets according to the preparation method described in the technical scheme.

Embodiment 2

[0022] Example 2, Ipagliflozin L-proline 25g, glimepiride 1g, chitosan 12g, calcium hydrogen phosphate 8g, microcrystalline cellulose 50g, povidone K30 10g, micronized silica gel 8g, stearic acid Magnesium 2g. Prepare 1000 tablets according to the preparation method described in the technical scheme.

Embodiment 3

[0023] Example 3, Ipagliflozin L-proline 20g, glimepiride 2g, chitosan 10g, calcium hydrogen phosphate 10g, microcrystalline cellulose 45g, povidone K30 6g, micronized silica gel 12g, stearic acid Magnesium 1g. Prepare 1000 tablets according to the preparation method described in the technical scheme

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an ipagliflozin composition and belongs to the technical field of pharmaceutical preparations. The technical scheme of the present invention is: a kind of Ipagliflozin L-proline tablet composition, in the tablet of unit dose, contain Ipagliflozin L-proline 10-25mg, glimepiride 1- 2mg, chitosan 8‑12mg, calcium hydrogen phosphate 8‑16mg, microcrystalline cellulose 28‑50mg, povidone K30 3‑10mg, micronized silica gel 8‑16mg, magnesium stearate 1‑2mg. The technical scheme of the invention has positive effects on clinical application.

Description

technical field [0001] The invention relates to an ipagliflozin composition and belongs to the technical field of pharmaceutical preparations. Background technique [0002] Ipagliflozin, whose English name is ipragliflozin, was approved for marketing in Japan in January 2014. There are 25mg and 50mg specifications. The original research company is Astellas Japan. It is a selective sodium / sodium-glucose transporter 2 (SGLT2) inhibitor that inhibits glucose reuptake by selectively inhibiting SGLT2, thereby lowering blood sugar. A Phase III pivotal trial of Ipagliflozin monotherapy and multiple clinical studies of the drug in combination with other hypoglycemic drugs supported the approval of this product in Japan. This medicine is made and sold by Astellas Corporation. [0003] Although Ipagliflozin has a good hypoglycemic effect, its chance of causing urinary tract infection is as high as 20%. Such a high adverse reaction affects its clinical application. Contents of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/64A61K31/381A61K31/401A61K9/20A61K47/36A61K47/02A61P3/10
Inventor 孙爱梅
Owner WEIHAI GUANBIAO INFORMATION TECH